Vera Therapeutics — Third Quarter 2026 Earnings Summary

Vera Therapeutics reported $10.3 million in net product revenue for the third quarter of 2026 following the U.S. launch of TRUTAKNA, which received accelerated FDA approval in July. The company presented final efficacy data from the ORIGIN 3 trial showing a 76% reduction in the risk of kidney disease progression and has submitted a supplemental Biologics License Application for full approval. Vera Therapeutics reported a net loss of $93.7 million for the quarter, driven by increased selling, general, and administrative expenses related to the commercial launch, while maintaining $384 million in cash and marketable securities.